skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Labetuzumab-SN-38 Immunoconjugate IMMU-130 (Code C95710)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Labetuzumab-SN-38 Immunoconjugate IMMU-130

Definition: An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor SN-38, with antineoplastic activity. The monoclonal antibody moiety of antibody-drug conjugate IMMU-130 selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.

Display Name: Labetuzumab-SN-38 Immunoconjugate IMMU-130

Label: Labetuzumab-SN-38 Immunoconjugate IMMU-130

NCI Thesaurus Code: C95710 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL428175  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Antibody-Drug Conjugate IMMU-130
Labetuzumab-SN-38 Immunoconjugate IMMU-130

External Source Codes: 
PDQ Closed Trial Search ID 692828
PDQ Open Trial Search ID 692828 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C95710
Contributing_Source CTRP
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom